ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 170 filers reported holding ASCENDIS PHARMA A/S in Q3 2021. The put-call ratio across all filers is 1.45 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $46,642 | -6.8% | 342 | +3.3% | 0.00% | -25.0% |
Q1 2024 | $50,038 | +24.9% | 331 | +4.1% | 0.00% | +33.3% |
Q4 2023 | $40,053 | +156.1% | 318 | +90.4% | 0.00% | +50.0% |
Q3 2023 | $15,638 | -10.6% | 167 | -14.8% | 0.00% | 0.0% |
Q2 2023 | $17,493 | -41.5% | 196 | -29.7% | 0.00% | -33.3% |
Q1 2023 | $29,915 | -30.0% | 279 | -20.3% | 0.00% | -40.0% |
Q4 2022 | $42,746 | +47.4% | 350 | +25.4% | 0.01% | +25.0% |
Q3 2022 | $29,000 | +81.2% | 279 | +59.4% | 0.00% | +100.0% |
Q2 2022 | $16,000 | -33.3% | 175 | -14.6% | 0.00% | -33.3% |
Q1 2022 | $24,000 | -33.3% | 205 | -22.3% | 0.00% | -25.0% |
Q4 2021 | $36,000 | +5.9% | 264 | +23.9% | 0.00% | -20.0% |
Q3 2021 | $34,000 | +47.8% | 213 | +23.8% | 0.01% | +66.7% |
Q2 2021 | $23,000 | +155.6% | 172 | +145.7% | 0.00% | +200.0% |
Q1 2021 | $9,000 | +28.6% | 70 | +59.1% | 0.00% | 0.0% |
Q4 2020 | $7,000 | +75.0% | 44 | +63.0% | 0.00% | 0.0% |
Q3 2020 | $4,000 | 0.0% | 27 | +3.8% | 0.00% | 0.0% |
Q2 2020 | $4,000 | – | 26 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RA Capital Management | 4,240,536 | $300,484,000 | 16.06% |
Sofinnova Investments, Inc. | 2,479,514 | $175,698,000 | 15.66% |
Vivo Capital, LLC | 2,166,832 | $153,542,000 | 15.48% |
VHCP Management II, LLC | 504,210 | $35,728,000 | 9.54% |
EcoR1 Capital, LLC | 1,087,257 | $77,043,000 | 6.94% |
Avoro Capital Advisors LLC | 1,963,336 | $139,122,000 | 6.39% |
Foresite Capital Management IV, LLC | 245,424 | $17,391,000 | 5.70% |
Eventide Asset Management | 1,544,900 | $109,472,000 | 4.02% |
Orbimed Advisors | 4,155,891 | $294,486,000 | 3.55% |
Ghost Tree Capital, LLC | 225,000 | $15,944,000 | 3.39% |